2007 Press Releases

requires Adobe Reader

Biowa And Lonza Enter Into Strategic Collaboration To Generate Optimized Production Platform For More Potent Antibodies

Oct 24, 2007

Biowa Announces Extended Licensing To Medimmune Of Biowa’s Potelligent^® Technology For Use In Antibody Research And Development

Oct. 19,2007

Biowa Announces Licensing Of Biowa’s Potelligent^® Technology By Glaxosmithkline For Use In Antibody Research And Development

July 30,2007

Biowa Introduces Its Second Technology To Dramatically Enhance Antibody Effector Function And The Launch Of AccretamabEplatform

July 23rd, 2007

Phase 1 Interim Clinical Study Data Released Regarding Mild Asthma Anti-Il-5 Receptor Mab

May 30, 2007

Biowa And Takeda Announce Licensing Ofbiowa’s Potelligent^® Technology For Use In Antibody Research And Development

February 5, 2007

UCB Licenses Biowa’s Potelligent^® Technology For Use In Antibody Research And Development

January 9, 2007

Biowa And Medarex Announce Allowance Of Investigational New Drug Application For Second-Generation Anti-Cd30 Antibody (Mdx-1401) Enhanced Using Potelligent^® Technology